Background. Artemisinin-based combination therapy (ACT) is the first-line treatment of Plasmodium falciparum malaria. Since the introduction of artemether-lumefantrine (AL) for treatment of uncomplicated malaria in Sweden, treatment failures have been reported in adults.
METHODS

Study Population
Patients aged ≥18 years with microscopy-confirmed P. falciparum malaria treated in Stockholm between January 2000 and June 2015 were included in this retrospective study. Ethical permission was obtained from the Central Ethical Review Board in Stockholm (2012/1155-32). Written informed consent was obtained for blood sampling during follow-up. Patients were identified at the Department of Microbiology at Karolinska University Hospital (Huddinge and Solna), the only laboratories performing malaria diagnostics in Stockholm. Completeness of data was assured through the national surveillance data at the Public Health Agency of Sweden based on mandatory reporting from physicians and diagnostic laboratories. Medical records were retrieved from Karolinska University Hospital (Solna and Huddinge sites), Danderyd Hospital, St Göran Hospital, and Stockholm South Hospital. The records were reviewed for collection of clinical, laboratory, and epidemiological data. Patients diagnosed with only gametocytes after previous treatment elsewhere were excluded. Severe malaria was defined according to WHO criteria [10] and the additional criterion of hyperparasitemia >5%.
Microscopy
Conventional light microscopy of Field-or Giemsa-stained thin and thick smears was performed for detection, species classification, and enumeration of parasitemia (percentage of infected erythrocytes) by expert microscopists at Karolinska University Hospital.
Antimalarial Treatment Regimens
Six doses of AL (4 tablets of 80 mg artemether and 480 mg lumefantrine, Riamet, Novartis, twice daily for 3 days) is the first-line treatment of uncomplicated P. falciparum malaria in Stockholm since 2010. Patients with severe disease or vomiting are initially administered intravenous artesunate followed by a full course of oral AL. Prior to 2010, the first-line treatment for P. falciparum was mefloquine (Lariam, Roche) and occasionally atovaquone-proguanil (AP; Malarone, GlaxoSmithKline), with quinine used as intravenous treatment. Mefloquine was exchanged as first-line treatment to avoid adverse effects.
Treatment Failure
Early treatment failure, occurring during the first week of treatment, was defined as 1 or more of (i) clinical deterioration to severe malaria, (ii) parasites persisting day 3 and onward, or (iii) parasitemia increasing on day 2 after initiated treatment. Late treatment failure was defined as parasites reappearing 7-42 days after a microscopy-negative interval [11] . All patients in Sweden have a personal number identifying them through all their respective healthcare contacts, thus allowing detection of multiple admissions or recrudescent parasitemia treated in Stockholm during the 15-year study period.
For the analysis of effectiveness, only patients with oral antimalarial regimens were included. Treatment changes due to reasons other than a poor clinical response (eg, adverse effects) were reported within the mixed-treatment group.
To elucidate reasons for AL treatment failures, parasite genotyping and analyses of plasma drug concentrations were performed on samples available from patients with late treatment failures. These samples were collected at the acute admission, after approximately 10 days and 1 month as part of an ongoing malaria immunology study.
Genotyping of Parasite Populations and Drug Resistance Markers
DNA was extracted from packed blood cells using commercial extraction kits (Blood Mini Kit, Qiagen). The polymorphic merozoite surface protein 2 gene (msp2) was genotyped for characterization of P. falciparum parasite populations [12] . Furthermore, single-nucleotide polymorphisms (SNPs) associated with drug resistance were analyzed, including P. falciparum chloroquine transporter (pfcrt) 72-76 [13] ; P. falciparum multidrug resistance gene 1 (pfmdr1) N86Y, Y184F, S1034C, N1042D, F1226Y, and D1246Y [13, 14] ; as well as 4 SNPs in the propeller region of the kelch motif-containing gene, K13, which has been associated with artemisinin resistance in Southeast Asia [15] .
Lumefantrine and Desbutyl-Lumefantrine Concentrations
Frozen plasma samples collected in EDTA were analyzed at the Department of Clinical Pharmacology, Karolinska University Hospital. Liquid chromatography coupled to liquid chromatography-tandem mass spectrometry (LC-MS/ MS) was used to measure plasma concentrations of lumefantrine (LUM) and its metabolite desbutyl-lumefantrine (DBL) [16] . DBL is the main metabolite of LUM and has potent antimalarial activity [17] . The method allows measurements of LUM and DBL down to 21 ng/mL and 1.9 ng/mL, respectively, with an intra-and interassay precision of <10% (coefficent of variation) and accuracy within ±10% for both LUM and DBL.
Statistical Analysis
Statistical analyses were performed with Stata software version 13 (StataCorp Among the 87 cases with initial intravenous therapy, 38 (43.7%) received artesunate with AL as oral follow-up, and 49 (56.3%) received quinine or quinine and artesunate followed by various oral treatments. Age, sex, body weight, and patient origin were similar between treatment groups (Table 1) .
Treatment Outcome
Five late treatment failures were recorded in patients treated with AL only (n = 95; Table 1 ). Among patients receiving AP Table 2 ).
Clinical Description of Cases With Recrudescence After AL Therapy
All 5 patients experiencing recrudescent parasitemia after an interval of 20-28 days after treatment start were men; 4 were born in Sweden and 1 in France (Table 3 ). All had been admitted to hospital for treatment of uncomplicated P. falciparum malaria and had an adequate initial treatment response and were parasite negative by microscopy latest on the second day after initiated AL treatment of admission. Each dose was administered by a ward nurse who documented intake in the medical record, and compliance according to documentation was 100%. The patients were 20-58 years old with body weight 69-121 kg (median, 77 kg), and none had coexisting disease or daily medications at the time of admission. Four patients had visited Africa: 2 Ghana, 1 Tanzania, and 1 Tanzania and Mozambique; 1 had backpacked in Southeast Asia (Thailand, Cambodia, Vietnam, and Indonesia) ( Table 3 ). The recrudescent parasitemia resolved quickly after initiated re-treatment in all cases (Figure 1 ).
Drug Concentrations, Parasite Genotyping and Microscopy in Cases With Treatment Failure After AL Therapy
Concentrations of LUM and DBL were analyzed in plasma samples. For case 1, drug concentrations were analyzed at Mahidol University in Bangkok, as published elsewhere [9] . No samples were available for case 2. Case 3 had a LUM concentration of 233 ng/mL 2 hours after completion of 6 AL doses during his first admission and 2250 ng/mL 48 hours after the last dose of the second AL course. Case 4 had anorexia and poor food intake reported during his first admission, and LUM concentration was 792 ng/mL after dose 2 and 23.5 ng/mL 14 days after initiation of treatment. Case 5 had LUM concentration of 441 ng/mL 10 hours after the sixth dose of AL during the first admission and 26.7 ng/mL day 13 after treatment start. He was successfully re-treated with AL and given a total of 10 doses over 5 days in combination with doxycycline. LUM concentration shortly after dose 8 in this regimen was 4200 ng/mL (Supplementary Table 1 , Figure 1) .
Genotyping of msp-2 confirmed that parasites of the same clone reappeared at the second admission in cases 1, 4, and 5. No samples were available for case 2. For case 3, the sample available from the first admission was from day 3 after initiation of treatment, and both microscopy and polymerase chain reaction (PCR) were negative at this time point. At the second wave of infection, 2 different P. falciparum clones (ie, 2 genetically distinct parasite populations) were detected by PCR. Genotyping of drug resistance-associated markers revealed both pfcrt wild-type and mutant genotypes, whereas for pfmdr-1 all genotyped loci in all samples were of wild type (Table 4) . Genotyping of parasites from case 5 who had traveled through countries where artemisinin resistance occurs (Cambodia, Vietnam, and Thailand) had a mutation at 1 of 4 genotyped loci of the K13 propeller allele present in all samples, whereas all other failure cases had K13 wild-type parasites. Cases 1, 4, and 5 had samples available from the period when they were asymptomatic (day 6, 9, and 13, respectively) after initiated treatment and were parasite negative by microscopy, whereas P. falciparum msp-2 was amplified at the same time points (Table 4) .
DISCUSSION
This report highlights a high frequency of late AL treatment failures in adult travelers treated for uncomplicated P. falciparum malaria. Analysis of all malaria cases in adults in Stockholm during 15 years revealed that among 95 patients treated with AL for uncomplicated episodes, 5 had late treatment failures (5.2 %). In contrast, no failure was found with the previously used first-line treatment MQ. Interestingly, all failures were in nonimmune men of European origin and the failure rate in this group was as high as 27%.
AL is the most widely used artemisinin-based combination therapy, and high efficacy is well documented in studies from endemic areas, mainly in African children with an overall efficacy of 97% [3] . The few studies evaluating AL in travelers report similar (96%) efficacy [4, 5] , and AL is recommended by WHO for the treatment of malaria also in nonimmune patient populations [1] . Nonetheless, treatment failures of 6 doses of AL have been reported in travelers in smaller studies and case reports, again predominantly in adult men (summarized in Table 5 ) [6-10, 18, 19] .
A noncomparative study of efficacy of AL in nonimmune adults showed 100% efficacy in patients with body weight <65 kg and 93.4% in those weighing ≥65 kg [4] . In that study, plasma concentrations of lumefantrine and desbutyl-lumefantrine were weakly and negatively correlated with body weight. Here, although all treatment failures were in men 69-121 kg, we could not confirm the difference in efficacy in patients with different weight classes when using 65 kg as a cutoff; this, however, likely represents the fact that only a minority (13%) of patients had body weight <70 kg. Women represented one-third of patients and only 4 Swedish-born women were treated with AL. A larger study sample would be needed to elucidate if the decreased effectiveness is specific to males and explained by, for example, different distribution volumes or higher body weight.
Day 7 plasma concentrations of lumefantrine is suggested as a marker of adequate drug concentration, with lumefantrine <280 ng/mL [20] or <200 ng/mL [21] proposed as thresholds. Modeling day 7 concentrations in our patients with treatment failure was restricted by the limited number of follow-up samples and sample timing not optimized for analysis of concentration dynamics. Compared to a study in Tanzania where plasma lumefantrine concentrations during first 2 days of treatment were 1000-1500 ng/mL [22] , all cases in our study who later presented with recrudescent parasitemia had substantially lower lumefantrine concentrations during the initial AL treatment, most pronounced in cases 3 and 5, whereas case 1 appeared to have adequate lumefantrine concentration on day 6.
Although limited by its retrospective study design, our study is to our knowledge the largest comparative study in adult travelers. In addition, a strength of our study is that effectiveness of antimalarial treatment is performed in a malaria-free area, thus ruling out the possibility of recrudescent parasitemia being a result of reinfection.
Parasite genotyping confirmed that all infections were recrudescence. To clarify if drug resistance contributed to the treatment failures described, we analyzed molecular markers associated with antimalarial drug resistance. Samples from all cases were of pfmdr 86N [23] . Moreover, 2 cases had the pfcrt K76 (wild-type) allele, which has been associated with increased lumefantrine tolerance [24] [25] [26] . Genotyping of parasites from the patient who had traveled through countries in Southeast Asia where artemisinin resistance occurs [27] revealed a mutation at 1 SNP in the K13-propeller region. Although this is a warning sign of emerging artemisinin resistance, a single mutation cannot fully explain the recrudescence of parasites. Because the initial clinical response was rapid, it is unlikely that resistance to artemether was of major importance in this case. For all cases, the genotyping results indicate that treatment failures were unlikely to be caused by drug-resistant parasites.
AL was originally introduced as a 4-dose regimen, but was changed to a 6-dose regimen after studies demonstrating poor efficacy as well as inadequate lumefantrine concentrations [28] [29] and unsatisfactory cure rates with 4 doses in trials in Southeast Asia (where multidrug-resistant parasites are common and the population has a lower degree of immunity) [30, 31] . At the time of registration of AL, there was almost no data from nonimmune or heavier patients, and the US Food and Drug Administration posed a requirement for postmarketing evaluation of efficacy in heavier-weight populations [32] .
According to a recent pooled analysis of studies performed in malaria-endemic areas, a total lumefantrine dose of <60 mg/kg had the lowest efficacy in curing P. falciparum and this group of patients accounted for 41% of the treatment failures [3] . The standard dose of 4 tablets at 6 time points for adults and children weighing ≥35 kg contains a total of 2880 mg lumefantrine. In patients weighing 70 kg, a standard 6-dose regime thus results in a total dose of lumefantrine of 41 mg/kg and only 32 mg/kg in patients weighing 90 kg.
In the previous pooled analysis, the lumefantrine dose administered predicted recrudescence in Asia but not in Africa [3] , suggesting the importance of background immunity for the efficacy of AL in areas with higher endemicity. A study from Kilifi, Kenya, demonstrated declining responsiveness of AL treatment in parallel with declining transmission and thus population-level immunity [33] . These findings are interesting as all cases of treatment failure reported in our study were in previously malaria-naive individuals.
One plausible reason for the treatment failures described here is thus that the parasites were not adequately exposed to lumefantrine. Increasing the administration to a 5-day (augmented) regimen might circumvent the problems with low and unpredictable oral uptake of lumefantrine in the initial phase of treatment and increase the area under the curve of lumefantrine plasma concentration and thus affect the therapeutic outcome. Moreover, a treatment regime against a potentially severe and lethal infection as P. falciparum should have a safety margin allowing for single doses to be missed or for limited absorption in the initial phase of disease, especially in vulnerable and nonimmune patient groups. An ongoing randomized 2-arm trial in Myanmar compares 3 and 5 days of treatment with AL [34] . Moreover, ACTs other than AL are available for the treatment of uncomplicated malaria in nonendemic areas [19, 35] . In summary, our report indicates an unsatisfactory frequency of symptomatic AL treatment failures in nonimmune adults and emphasizes the need to further monitor and evaluate the efficacy of this current drug regimen. Notably, all patients with recrudescent parasitemia were nonimmune men, similar to previously published reports, suggesting that dosage of AL is insufficient for this group. More research regarding dosing schemes is needed. Clinicians and patients need to be aware of the possibility of parasites reappearing several weeks after initial treatment.
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